-transparent.png){kind=logo}
The human lymphoblast line MGL8 was treated with HAT and subsequently "mutagenized" with EMS (200 microgram/ml) to give 15% survival, and 6-thioguanine-resistant cells were selected by cloning in soft agarose containing the drug (1 microgram/ml). Eighteen sublines of independently derived resistant clones were isolated and studied in detail. One subline had a low residual HGPRT activity of about 1% of the parental cells. The HGPRT of this subline had a higher Km for PRPP, was more sensitive to heat, and was degraded faster by trypsin than the enzyme in extracts of MGL8 cells. This resistant subline and three others contained CRM levels of 1--38%, compared to the wild-type, so they probably represent true structural mutants of the HGPRT gene. All the variants maintained the karyotype of the parental line (46, XY, 6p-).
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
December 1996,
Nihon rinsho. Japanese journal of clinical medicine,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
February 1976,
Human genetics,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
June 1969,
Biochemical genetics,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
April 1979,
Biochemical pharmacology,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
May 1975,
Archives of biochemistry and biophysics,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
March 1978,
The Journal of pediatrics,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
January 1973,
Advances in experimental medicine and biology,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
October 1974,
Experimental cell research,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
September 1972,
Proceedings of the National Academy of Sciences of the United States of America,
J Epstein, and
A Leyva, and
W N Kelley, and
J W Littlefield
April 1988,
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
